Clinical Trials
321 trialsBreast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
National Institutes of Health Clinical Center (CC)
Risk Communication Within Mexican-American Families
National Institutes of Health Clinical Center (CC)
BRCA Mutations in Latinas
National Institutes of Health Clinical Center (CC)
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
National Institutes of Health Clinical Center (CC)
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Breast Mammogram and Tissue Study
National Institutes of Health Clinical Center (CC)
Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
National Institutes of Health Clinical Center (CC)
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Veliparib With or Without Carboplatin in Treating Patients With Stage III or IV Breast Cancer
National Cancer Institute (NCI)
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
National Cancer Institute (NCI)
An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin
National Institutes of Health Clinical Center (CC)
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
National Cancer Institute (NCI)
Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer
National Cancer Institute (NCI)
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
National Cancer Institute (NCI)
Eligibility Screening for the NIH Intramural Research Program Clinical Protocols
National Institutes of Health Clinical Center (CC)
Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
National Cancer Institute (NCI)
Where Culture Meets Genetics: Exploring Latinas Causal Attributions of Breast and Colon Cancer and Models of Disease Inheritance
National Institutes of Health Clinical Center (CC)
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
National Institutes of Health Clinical Center (CC)
Is it Feasible?: Self-Affirmation for Hereditary Breast and Ovarian Cancer Genetic Counseling
National Institutes of Health Clinical Center (CC)
The Treatment of Stage I and II Carcinoma of the Breast With Mastectomy and Axillary Dissection Versus Excisional Biopsy, Axillary Dissection, and Definitive Irradiation
National Institutes of Health Clinical Center (CC)
Sorafenib in Treating Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Vaccine Therapy in Treating Patients With Metastatic Cancer
National Cancer Institute (NCI)
A Follow-up Study of Women Evaluated and Treated for Infertility
National Institutes of Health Clinical Center (CC)
Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
National Cancer Institute (NCI)
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
National Cancer Institute (NCI)
Whole-Brain Radiation Therapy or Stereotactic Radiosurgery With or Without Lapatinib Ditosylate in Treating Patients With Brain Metastasis From HER2-Positive Breast Cancer
National Cancer Institute (NCI)
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
National Cancer Institute (NCI)
Follow-up Protocol for Patients With Cancer/AIDS/Skin Disease
National Institutes of Health Clinical Center (CC)
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
National Cancer Institute (NCI)
High-Risk Breast Duct Epithelium
National Institutes of Health Clinical Center (CC)
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
National Cancer Institute (NCI)
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
National Cancer Institute (NCI)
Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing
National Institutes of Health Clinical Center (CC)
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive
National Institutes of Health Clinical Center (CC)
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
National Cancer Institute (NCI)
Self-Affirmation: Construct Validity
National Institutes of Health Clinical Center (CC)
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations
National Institutes of Health Clinical Center (CC)
Tipifarnib and Combination Chemotherapy in Treating Patients With Stage II or Stage III Breast Cancer
National Cancer Institute (NCI)
Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
National Institutes of Health Clinical Center (CC)
The Ultrasound Study of Tamoxifen
National Institutes of Health Clinical Center (CC)
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
National Institutes of Health Clinical Center (CC)
Continuation of Follow-up of DES-Exposed Cohorts
National Institutes of Health Clinical Center (CC)